GSK wins FDA approval for neladalkib lung cancer drug from Nuvalent deal
The FDA granted accelerated approval to GSK's oral lung cancer drug neladalkib (Nelkarmi) for patients with advanced RET-altered non-small cell lung cancer, the second regulatory win from its $10.6 billion Nuvalent acquisition.